Variables | PFS | OS | ||
Univariate | Multivariate | Univariate | Multivariate | |
Sex | ||||
Male | 1 | 1 | 1 | |
Female | HR=0.7 (0.5 to 1.1), p=0.12 | HR=0.6 (0.4 to 1), p=0.07 | HR=0.6 (0.2 to 1.3), p=0.21 | |
Age at diagnosis | ||||
≤60 | 1 | 1 | ||
>60 | HR=0.9 (0.6 to 1.4), p=0.64 | HR=0.8 (0.5 to 1.3), p=0.37 | ||
Smoking status | ||||
Never smoker | 1 | 1 | ||
Current or former smoker | HR=0.6 (0.3 to 1.5), p=0.32 | HR=0.6 (0.2 to 1.8), p=0.42 | ||
Histological type | ||||
Adenocarcinoma | 1 | 1 | ||
Other | HR=1 (0.6 to 1.5), p=0.89 | HR=1 (0.6 to 1.6), p=0.9 | ||
WHO performance status | ||||
0 | 1 | 1 | 1 | |
>0 | HR=1.2 (0.7 to 2.1), p=0.42 | HR=2.9 (1.3 to 6.2), p=0.007 | HR=1.6 (0.6 to 4.2), p=0.3 | |
Cerebral metastasis | ||||
No | 1 | 1 | ||
Yes | HR=1.4 (0.8 to 2.4), p=0.25 | HR=1.1 (0.6 to 2.2), p=0.7 | ||
Liver metastasis | ||||
No | 1 | 1 | ||
Yes | HR=1.2 (0.7 to 2), p=0.56 | HR=1.1 (0.6 to 2.1), p=0.7 | ||
Bone metastasis | ||||
No | 1 | 1 | 1 | 1 |
Yes | HR=2.1 (1.2 to 3.5), p=0.006 | HR=2.8 (1.5 to 5.1), p=0.001 | HR=2.7 (1.4 to 5.3), p=0.002 | HR=3.7 (1.6 to 8.5), p=0.002 |
Lymph node metastasis | ||||
No | 1 | 1 | ||
Yes | HR=0.6 (0.3 to 1.2), p=0.13 | HR=0.8 (0.3 to 1.8), p=0.56 | ||
Pleuroperitoneal metastasis | ||||
No | 1 | 1 | ||
Yes | HR=1.4 (0.8 to 2.5), p=0.21 | HR=1.3 (0.7 to 2.4), p=0.46 | ||
Line of ICI | ||||
1 | 1 | 1 | ||
>1 | HR=0.9 (0.6 to 1.3), p=0.53 | HR=1.4 (0.8 to 2.4), p=0.2 | ||
Type of ICI | ||||
Anti-PD-1 | 1 | 1 | ||
Anti-PD-L1 | HR=1.3 (0.5 to 3), p=0.63 | HR=1.4 (0.5 to 3.8), p=0.51 | ||
Anti-PD-L1+anti-CTLA4 | HR=1.2 (0.5 to 3), p=0.68 | HR=0.75 (0.2 to 2.4), p=0.62 | ||
Anti-PD-1+anti-CTLA4 | HR=0.86 (0.21 to 3.5), p=0.83 | HR=0.6 (0.1 to 4.6), p=0.66 | ||
Other association | HR=3.6 (0.5 to 26), p=0.21 | – | ||
PD-L1 status (cut-off at 1%) | ||||
Negative tumors | 1 | 1 | ||
Positive tumors | HR=0.6 (0.3 to 1.1), p=0.13 | HR=0.7 (0.3 to 1.4), p=0.27 | ||
LDH | HR=1 (1 to 1), p=0.12 | HR=1 (1 to 1), p=0.01 | ||
dNLR | HR=1.2 (1 to 1.5), p=0.01 | HR=1.5 (1.2 to 1.8), p<1×10−3 | ||
LIPI score | ||||
0 | 1 | 1 | 1 | 1 |
>0 | HR=2.2 (1.2 to 3.8), p=0.008 | HR=2.4 (1.3 to 4.5), p=0.003 | HR=3 (1.5 to 6.1), p=0.002 | HR=2.8 (1.3 to 6), p=0.006 |
EGFR | ||||
WT | 1 | 1 | ||
Mutated | HR=0.65 (0.2 to 2.7), p=0.55 | HR=0.4 (0.05 to 2.8), p=0.34 | ||
KRAS | ||||
WT | 1 | 1 | 1 | |
Mutated | HR=1.2 (0.7 to 2.1), p=0.51 | HR=2 (1.1 to 3.7), p=0.03 | HR=1.8 (0.8 to 4), p=0.16 | |
BRAF | ||||
WT | 1 | 1 | 1 | |
Mutated | HR=12.3 (2.6 to 58), p=0.001 | HR=19.6 (3.6 to 107), p<1×10−3 | HR=1.3 (0.2 to 9.7), p=0.78 | |
MET | ||||
WT | 1 | 1 | ||
Mutated | HR=1.3 (0.3 to 5.5), p=0.72 | HR=1.6 (0.4 to 6.6), p=0.54 | ||
MER4 | ||||
Low | 1 | 1 | 1 | 1 |
High | HR=0.3 (0.2 to 0.6), p<1×10−3 | HR=0.4 (0.1 to 1.1), p=0.06 | HR=0.4 (0.2 to 0.8), p=0.01 | HR=0.4 (0.1 to 1.3), p=0.11 |
Multivariate Cox models were constructed using variables significantly associated with survival by univariate Cox models (with a p<0.1). As the LIPI score was selected, LDH and dNLR were not included because these variables are used to compute the LIPI score.
ICI, immune checkpoint inhibitors; LIPI, Lung Immune Prognostic Index; OS, overall survival; PD-1, programmed death-1; PFS, progression-free survival.